Cencora Inc. (COR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cencora Inc. stock (COR) is currently trading at $327.27. Cencora Inc. PE ratio is 39.20. Cencora Inc. PS ratio (Price-to-Sales) is 0.20. Analyst consensus price target for COR is $410.38. WallStSmart rates COR as Hold.
- COR PE ratio analysis and historical PE chart
- COR PS ratio (Price-to-Sales) history and trend
- COR intrinsic value — DCF, Graham Number, EPV models
- COR stock price prediction 2025 2026 2027 2028 2029 2030
- COR fair value vs current price
- COR insider transactions and insider buying
- Is COR undervalued or overvalued?
- Cencora Inc. financial analysis — revenue, earnings, cash flow
- COR Piotroski F-Score and Altman Z-Score
- COR analyst price target and Smart Rating
Cencora Inc.
📊 No data available
Try selecting a different time range
COR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Cencora Inc. (COR)
COR trades 44% above its Graham fair value of $254.20, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Cencora Inc. (COR) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around operating margin and price/book. Fundamentals are solid but monitor weak areas for improvement.
Cencora Inc. (COR) Key Strengths (5)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $134 in profit
Paying less than $1 for every $1 of annual revenue
96.87% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Cencora Inc. (COR) Areas to Watch (5)
Near-zero operating margins, business under pressure
Very expensive at 33.3x book value
Very thin margins, barely profitable
Modest revenue growth at 5.50%
Solid earnings growth at 14.80%
Supporting Valuation Data
Cencora Inc. (COR) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, Price/Sales. Valuation metrics including PEG Ratio (0.78), Price/Sales (0.20) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 133.50%.
The Bear Case
The primary concerns are Operating Margin, Price/Book, Profit Margin. Some valuation metrics including Price/Book (33.32) suggest expensive pricing. Growth concerns include Revenue Growth at 5.50%, EPS Growth at 14.80%, which may limit upside. Profitability pressure is visible in Operating Margin at 1.18%, Profit Margin at 0.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 133.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 5.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Return on Equity) and negatives (Operating Margin, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
COR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
COR's Price-to-Sales ratio of 0.20x trades 63% above its historical average of 0.12x (96th percentile), historically expensive. The current valuation is 11% below its historical high of 0.22x set in Mar 2026, and 290% above its historical low of 0.05x in Jun 2009. Over the past 12 months, the PS ratio has compressed from ~0.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cencora Inc. (COR) · HEALTHCARE › MEDICAL DISTRIBUTION
The Big Picture
Cencora Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 325.8B with 6% growth year-over-year. Profit margins are thin at 0.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 133.5% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -2.4B, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Cencora Inc. push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL DISTRIBUTION industry trends, competitive moves, and regulatory changes that could impact Cencora Inc..
Bottom Line
Cencora Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cencora Inc.(COR)
NYSE
HEALTHCARE
MEDICAL DISTRIBUTION
USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.